A Decade of Human Connection: Workhuman Wraps It's Tenth Workhuman Live Conference; Announces Workhuman Live 2026 in Orlando, Florida
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- Workhuman ®, the world's leading employee recognition company, wrapped the tenth instance of its flagship event Workhuman Live, in Denver, where thousands of HR leaders gathered to reimagine what it means to create thriving workplace cultures. This year's Workhuman Live wasn't just a look ahead—it was a mirror held up to the profession. It asked HR leaders not just to adapt to change, but to own it. To stop supporting from the sidelines and start architecting the future of work with data, dignity, and bold decisions.
From May 12–15, thousands of HR leaders, practitioners, and executives from around the globe gathered. The mainstage came alive with headlining speakers like Trevor Noah, Adam Grant, and a who's who of industry trailblazers, offering fresh insight into leadership, workplace culture, and the human experience at work. Workhuman customers shared how they're using recognition not as a perk, but as a performance strategy—showing measurable impact on engagement, retention, and inclusion.
'Workhuman Live has become more than a conference—it's an entire movement,' said Tom Libretto, President of Workhuman. 'It's where people leaders come to recharge, rethink their impact, and return to their organizations with the tools and momentum to build better workplaces.'
And this year's event proved that the work of the HR industry has never been more important. Among the many highlights, Workhuman and The Wall Street Journal Leadership Institute announced the launch of the inaugural CPO Council —a first-of-its-kind coalition bringing together visionary Chief People Officers to elevate the role of HR in shaping strategic business outcomes. The Council represents a bold step forward in redefining the impact of people leaders at the highest levels of the enterprise.
Innovations in Human Intelligence: Turning Recognition into a Live View of Workplace Culture
Another defining moment of this year's event was the debut of Workhuman Topics™, the newest addition to Workhuman's Human Intelligence™ suite. Topics uses advanced AI to turn recognition moments into a living, breathing map of how strategic priorities—like inclusion, innovation, or leadership behaviors—are actually showing up in the culture. No forms to fill out. No added workload. Just continuous, real-time insight into how values and strategies are being reinforced across every team, function, and geography.
Topics is the newest innovation in Workhuman's launch of Human Intelligence—new AI-powered tools that help companies understand what's really happening in their culture. While others focus on giving rewards, Workhuman leverages recognition data to help leaders see who's making an impact, how teams are working together, and where support is needed.
Workhuman Live 2026
The next frontier of business isn't digital, it's human. In a world driven by AI and automation, Workhuman is calling HR to lead with purpose, insight, and recognition as a growth lever. HR leaders are encouraged to enhance their learning, networking, and professional growth at Workhuman Live 2026, which will take place April 27–30, 2026 in Orlando, Florida. Early registration is now open at www.workhumanlive.com, and code WHL26PRESS will provide a 20% discount.
As attendees head back to their organizations, the message is clear: Workhuman is leading the next era of HR. One where recognition fuels performance, culture becomes a competitive advantage, and human intelligence drives business growth.
About Workhuman
Workhuman ® is the world's leading recognition and rewards platform, serving organizations of all sizes—from the Fortune 500 to fast-growing mid-market companies—across more than 180 countries. With over 25 years of category leadership, we support 7 million employees worldwide and have facilitated more than 100 million moments of connection that elevate culture and drive performance.
With over a decade of consistent profitability, Workhuman ® stands as proof that investing in people delivers lasting business value. Our pioneering Human Intelligence™ technology transforms recognition into strategic insight, empowering organizations to unlock the full potential of their people while driving measurable business impact and culture transformation.
Learn more at www.workhuman.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
12 minutes ago
- Business Wire
Circus SE Moves Global Headquarters to Munich
MUNICH--(BUSINESS WIRE)--Circus SE (XETRA: CA1), a global technology company in AI software and autonomous robotics for the food service industry, today announces the relocation of its global headquarters to Munich, marking a strategic move to strengthen its position in one of Europe's most dynamic technology hubs. With a strong foundation already laid in the region through years of mechanical engineering and robotics development, the company is doubling down on Munich as its core location for AI innovation, advanced robotics, and pre-series production of its new CA-M military-grade autonomous robot platform. 'As OpenAI, NVIDIA and other global leaders invest in Munich and the global demand for intelligent automation surges, Munich has become one of the few places in the world where cutting-edge research meets world-class engineering talent,' said Nikolas Bullwinkel, CEO and Founder of Circus. 'We're building the future of robotics here – from our civilian food service automation to next-gen defense solutions – and Munich will be our long-term launchpad.' The new HQ will serve as a central R&D hub, attracting top talent and enabling closer collaboration with leading universities, research centers, and the region's industrial base. 'The ecosystem in Munich is continuously evolving into a global hotspot for robotics and AI,' says Dr. Arne Rost, member of the Circus Advisory Board Member and Managing Director of the Venture Lab Robotics/AI from the Technical University Munich. 'The city brings together academic excellence, entrepreneurial drive, and international deep-tech talent – and Circus is one of the most ambitious companies actively shaping this ecosystem.' Circus' expansion signals a broader trend of global tech players choosing Munich as their base to scale high-impact innovation. With serial production underway and global deployments of its robotics system CA-1 lined up, Circus is set to redefine how intelligent machines integrate into everyday life — and Munich is where that future begins. About Circus SE Circus SE (XETRA: CA1) is a global technology company in the field of embodied AI and AI software for the food service industry, driving innovation and autonomy in labor-intensive sectors. With its core product, the CA-1 robot, Circus is a pioneer in applying embodied AI, integrating cutting-edge technologies into real-world operations, and transforming the food service industry. By combining advanced robotics, AI-driven software, and a mission to solve global challenges, Circus is shaping the future of autonomous systems and redefining human-AI collaboration. Headquartered in Germany and with a rapidly growing international presence, Circus leads the next generation of AI applications.
Business Wire
22 minutes ago
- Business Wire
Dubai Retains Global Top Spot for Attracting Greenfield FDI Projects in Cultural and Creative Industries in 2024
DUBAI, United Arab Emirates--(BUSINESS WIRE)--(Dubai Culture) Dubai has maintained its first place as the world's leading destination for greenfield foreign direct investment (FDI) in the cultural and creative industries (CCI), topping the Financial Times' fDi Markets ranking for the third consecutive year. The 2024 report, which assessed 233 cities under the 'Creative Industries Cluster' classification, placed Dubai ahead of global hubs such as London and Singapore. During the year, the emirate attracted 971 CCI projects—an 8% increase from 2023—bringing in AED 18.86 billion in capital inflows, up nearly 60% from 2023, and generating 23,517 new jobs, a 9% year-on-year rise. All major CCI subsectors saw stronger performance, with notable growth in advertising and PR, film and media production, gaming, education, and advanced software design. According to the Dubai FDI Monitor, greenfield, wholly-owned ventures made up 76.5% of all projects, while new forms of investment represented 15.4%, reinvestment 5.6%, and mergers & acquisitions (2.4%). Data from the Dubai FDI Monitor and the Dubai Framework for Cultural Statistics show that the United States accounted for the largest share of capital inflows in 2024, at 23.2%, followed by India (13.4%), the United Kingdom (9.4%), Switzerland (7.6%), and Saudi Arabia (4.8%). India led in both the number of projects (18.8%) and jobs (18.5%), while the UK, US, Germany, Italy, and France also featured prominently across both metrics. Investor confidence continues to be driven by Dubai's pro-business reforms, including Executive Council Resolution 11 of 2025, which enables free zone businesses to operate onshore, expanding commercial flexibility. The city's Zero Government Bureaucracy programme is also reducing red tape across more than 2,000 federal procedures. Combined with strong intellectual property protections and advanced digital infrastructure, these initiatives have helped establish a regulatory framework marked by efficiency, transparency, and ease of doing business. Insights from the ' Creative Dubai: Navigating Tomorrow's Creative Landscape' report illustrate how this ecosystem is scaling with demand, pinpointing investment opportunity hotspots in design, immersive media and AI-driven production. Dubai continues to offer investors access to top-tier talent, competitive setup costs, and strategic connectivity. The 2024 FDI results underscore the city's rise as a global hub for innovation and one of the world's most attractive environments for creative enterprise.
Business Upturn
40 minutes ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
